EGFR and metastatic neoplasm: Contrary to our efforts to reduce between-study heterogeneity through subgroup analysis restricted to metastatic colorectal cancer patients with metastatic disease treated with anti-EGFR therapies, a high degree of heterogeneity remained (P = 0.01, I2 = 73.3%).